» Articles » PMID: 14567019

The Etiology, Clinical Presentation, and Management of Pseudomyxoma Peritonei

Overview
Date 2003 Oct 22
PMID 14567019
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

PMP is a rare condition, which, although of "borderline malignancy," is invariably fatal. Difficulties exist with the definition of PMP. It has been broadly applied to include a heterogenous group of pathologic lesions that present clinically with "jelly belly" due to mucinous ascites. The relatively few reports in the literature commonly use different pathologic definitions, and there is no consensus on the point of separation between PMP and carcinomatosis secondary to a mucinous adenocarcinoma. Sugarbaker has suggested "the term pseudomyxoma peritonei syndrome be strictly applied to a pathologically and prognostically homogenous group of cases characterized by histologically benign peritoneal tumors that are frequently associated with an appendiceal mucinous adenoma." This definition excludes all cases with mucinous adenocarcinoma. The optimal treatment is undoubtedly complete tumor excision, by complex surgical peritonectomy procedures, taking on average 10 hours. Surgery is usually combined with intraperitoneal, and now intraoperative heated chemotherapy. These techniques have a high morbidity and mortality. The rarity of the condition, together with the risks associated with definitive treatment, suggests that such treatment ought to be centralized in a few centers, covering a large population. The search continues for safer, less aggressive treatments, but is hampered by a lack of hard evidence and the absence of experimental animal or human models to evaluate emerging strategies.

Citing Articles

Molecular characterization of Pseudomyxoma peritonei with single-cell and bulk RNA sequencing.

Ha Y, Park S, Kim S, Tak K, Kim J, Kim C Sci Data. 2025; 12(1):213.

PMID: 39910051 PMC: 11799422. DOI: 10.1038/s41597-025-04561-4.


Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.

Gibson J, Pengelly R, Mirandari A, Boukas K, Stanford S, Cecil T Cancer Med. 2024; 13(20):e70340.

PMID: 39435876 PMC: 11494485. DOI: 10.1002/cam4.70340.


Pseudomyxoma peritonei of appendiceal mucinous neoplasm origin: A case report and review of literature.

Mousa A, Nukaly H, Samman R, Fuadah S, Bin Saddiq B, Alshowaikhat S Radiol Case Rep. 2024; 19(12):6565-6573.

PMID: 39391033 PMC: 11465061. DOI: 10.1016/j.radcr.2024.08.158.


New insights in the management of pseudomyxoma peritonei.

Pastier C, de Hingh I, Goere D J Surg Oncol. 2024; 130(6):1316-1325.

PMID: 39206531 PMC: 11826005. DOI: 10.1002/jso.27842.


Long-term outcomes and survival analysis of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei at a newly established peritoneal malignancy centre in Japan.

Yano H, Gohda Y, Moran B, Suda R, Kokudo N Ann Gastroenterol Surg. 2024; 8(4):701-710.

PMID: 38957568 PMC: 11216784. DOI: 10.1002/ags3.12791.